Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/1/2021 | $3.00 | Buy | Maxim Group |
Maxim Group initiated coverage of Stealth BioTherapeutics with a rating of Buy and set a new price target of $3.00
15-12G - Stealth BioTherapeutics Corp (0001696396) (Filer)
EFFECT - Stealth BioTherapeutics Corp (0001696396) (Filer)
EFFECT - Stealth BioTherapeutics Corp (0001696396) (Filer)
Cognito Therapeutics, a Phase 3-ready disease-modifying digital therapeutics company, today announced the appointment of Gerald Chan, ScD. as Chairman of the Board. Cognito is a pioneer in using neuromodulation to engage novel targets of neuronal pathophysiology to achieve disease modification in neurodegenerative diseases. Dr. Chan is the co-founder of Morningside, a privately held venture capital and private equity firm. Since inception, Morningside has focused on the development and commercialization of novel scientific discoveries in both the life sciences and technology sectors. "The use of non-pharmacological interventions to treat neurocognitive decline represents a fundamental shif
Study did not meet primary endpoints of mean change in low luminance visual acuity (LLVA) and geographic atrophy (GA) progression Categorical improvement in LLVA, with >15% of elamipretide-treated patients gaining 2+ lines of vision at Week 48 Elamipretide demonstrated enhanced ellipsoid zone preservation through reduction of progressive attenuation, an important indicator of photoreceptor loss. Company to host conference call and webcast today at 8:30 a.m. ET BOSTON, May 2, 2022 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysf
BOSTON, Nov. 11, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the three months ended September 30, 2021 and announced recent business highlights. "We are excited to broaden our clinical development efforts with multiple new trial initiations expected over the coming months," said Reenie McCarthy, Chief Executive Officer at Stealth. "We are highly enthusia
BOSTON, Nov. 4, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it will report third quarter 2021 financial results on Thursday, November 11, before the market opens. Management will host a conference call at 8:30 am ET that day to discuss the financial results and provide a general business update. The call can be accessed by dialing (877)-407-0989 (domestic) or (201)-389-0
BOSTON, Nov. 16, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO) (the "Company" or "Stealth BioTherapeutics"), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today the completion of the merger (the "Merger") with Stealth Merger Sub Limited, an exempted company with limited liability incorporated under the law of the Cayman Islands ("Merger Sub"), pursuant to the previously announced Agreement and Plan of Merger, dated as of July 31, 2022 (the "Merger Agreement"), among the Company, Stealth Parent Limited, an exempted company with limited liabilit
SBT-272 Phase 1 safety and tolerability data support further clinical development SBT-272 was neuroprotective and reduced neuroinflammation in ALS preclinical model SBT-272 Granted Orphan Drug Designation for Treatment of ALS BOSTON, Nov. 1, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced encouraging Phase 1 data on the safety and tolerability of SBT-272, a next-generation small molecule designed to reach therapeutic concentrations in the brain and to restore mitochondrial structure and functi
BOSTON, Oct. 7, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today that it has called an extraordinary general meeting of shareholders (the "EGM"), to be held at 9:30 a.m. (New York City time) on November 15, 2022, at Foley & Lardner LLP, 111 Huntington Ave Suite 2600, Boston, MA 02199, to consider and vote on, among other matters, the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of July 31, 2022 (the "Merger Agreem
SC 13D/A - Stealth BioTherapeutics Corp (0001696396) (Subject)
SC 13D/A - Stealth BioTherapeutics Corp (0001696396) (Subject)
SC 13D/A - Stealth BioTherapeutics Corp (0001696396) (Subject)